Cheng Fang

Cheng Fang

Auto-generated profile, based on publicly available information

Cheng Fang

Shanghai University of Traditional Chinese Medicine 1 Department of Immunology and Pathogenic Biology, School of Integrative Medicine Shanghai, China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Virology
Verified
Journal Article
Open access
PDF file
PXPeng Xu
Peng Xu
ACAaron Yun Chen
Aaron Yun Chen
SGSafder S Ganaie
Safder S Ganaie
FCFang Cheng
Fang Cheng
WSWeiran Shen
Weiran Shen
Jianming QiuJianming Qiu
Jianming Qiu
Human parvovirus B19 (B19V) infection causes hematological disorders and is the leading cause of nonimmunological fetal hydrops during pregnancy. During infection, B19V expresses two structural proteins, VP1 and VP2, and three nonstructural proteins, NS1, 11-kDa, and 7.5-kDa. While NS1 is essential, 11-kDa plays an enhancing role in viral DNA replication. Here, we elucidated a mechanism underlying 11-kDa protein-regulated B19V DNA replication. 11-kDa is tightly associated with cellular growth factor receptor-bound protein 2 (Grb2) during infection. In vitro , 11-kDa interacts with Grb2 with high affinity through three proline-rich motifs, of which at least one is indispensable for the regulation of viral DNA replication. 11-kDa and Grb2 interaction disrupts extracellular signal-regulated kinase (ERK) signaling, which mediates upregulation of B19V replication. Thus, our study reveals a novel mechanism of how a parvoviral small nonstructural protein regulates viral DNA replication by interacting with a host protein that is predominately expressed in the cytoplasm.

26 August 2008 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
KLKajsa Löfgren
Kajsa Löfgren
FCFang Cheng
Fang Cheng
LFLars‐Åke Fransson
Lars‐Åke Fransson
KBKatarina Bedecs
Katarina Bedecs
KMKatrin Mani
Katrin Mani

16 January 2026 in Cancer Research
Verified
Journal Article
Open access
CFCheng Fang
Cheng Fang
GLGuanglei Li
Guanglei Li
MHMin Han
Min Han
YWYiming Wang
Yiming Wang
WYWenxia Yu
Wenxia Yu
SZShiguo Zhu
Shiguo Zhu
NK cells hold great promise for cancer immunotherapy owing to their intrinsic capacity to recognize and eliminate malignant cells. Nevertheless, broad clinical deployment is hindered by NK-cell properties like poor expansion and refractoriness to genetic modification, as well as by tumor immune-evasion mechanisms. In this study, we applied base-editing technology to precisely modify signal transduction in primary human NK cells, which achieved a high editing efficiency of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT) gene (>90%) in peripheral blood–derived NK (TIGIT BE-NK) cells. TIGIT editing forced tumor-derived CD155 to engage CD226 and thereby converted an inhibitory signal into an activating one that amplified NK-cell cytotoxicity. TIGIT BE-NK cells specifically targeted cancer cells across multiple tumor types and were validated as safe, with minimal off-target effects. Cryopreserved TIGIT BE-NK cells exhibited similar antitumor activity as fresh TIGIT BE-NK cells, supporting their potential as an “off-the-shelf” therapy. Combining TIGIT BE-NK cells and IL2 further improved antitumor immunity. Together, these results underscore the feasibility of using base editing to modify NK cells and significantly enhance their therapeutic potential for treating patients with cancer. Significance: Modifying a single base within the TIGIT gene in NK cells switches inhibitory signaling to an activating axis that enhances antitumor immunity, supporting base editing of immune cells as an immunotherapeutic strategy.


17 June 2026
Verified
Other
Open access
CFCheng Fang
Cheng Fang
GLGuanglei Li
Guanglei Li
MHMin Han
Min Han
YWYiming Wang
Yiming Wang
WYWenxia Yu
Wenxia Yu
SZShiguo Zhu
Shiguo Zhu
Supplementary Video S5 captures the dynamic cytotoxic activity of PB-NK and TIGIT BE-NK cells against PLC/PRF/5 tumor cells.(Related to figure 2E)

17 June 2026
Verified
Other
Open access
CFCheng Fang
Cheng Fang
GLGuanglei Li
Guanglei Li
MHMin Han
Min Han
YWYiming Wang
Yiming Wang
WYWenxia Yu
Wenxia Yu
SZShiguo Zhu
Shiguo Zhu
In vivo tracking of TIGIT BE-NK cells: pharmacokinetic and biodistribution analysis by IVIS and ddPCR